Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TolDCcitpep route-of-delivery study in rheumatoid arthritis
ISRCTN14999554Phase 2Active, not recruiting
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Jan 2024
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
01
Overview
Phase 2, randomised, open-label trial of tolDCcitpep in rheumatoid arthritis (RA) (5 arms), sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoints: Immunomodulation biomarkers at week 6 and Lymph node aspirate immunomodulation assessment at week 1. Started Jan 2024; status: active, not recruiting.
02
Drugs
tolDCcitpep
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ISRCTN14999554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14999554.